 |
|
|
| |
A Single Direct-acting Anti-viral Agent, ACH-3102, with Ribavirin is Able to Achieve a Robust Anti-viral Response in Subjects with Genotype 1b Chronic Hepatitis C Infection
|
| |
| |
Reported by Jules Levin
Presented at the 23rd Conference of The Asian Pacific Association for The Study of the Liver, Brisbane, Australia, March 12-15, 2014
A. Muir1, R. Brennan2, R. Herring, Jr. 3, A. Sheikh4, M. Ryan5, V. Rustgi6, V. Ankoma-Sey7, J. Fabrycki8, J. Freddo8, J. Hui8, M. Huang8, D. Patel8, L. Robarge8, H. Robison8, G. Yang8, Y. Zhao8, M. Deshpande8, David Apelian8, H. Kocinsky8
1Duke Clinical Research Institute, Durham, NC; 2Infectious Diseases Associates of Central Virginia, Lynchburg, VA; 3Quality Medical Research, Nashville, TN; 4Gastrointestinal Specialist of Georgia, PC, Marietta, GA; 5Digestive and Liver Disease Specialists, Norfolk, VA; 6Metropolitan Research, Fairfax, VA, 7Liver Associates of Texas, P.A., Houston, TX, 8Achillion Pharmaceuticals, Inc, New Haven, CT
EASL/2012: PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION NS5A INHIBITORS.....http://www.natap.org/2012/EASL/EASL_79.htm
EASL/2013: ACH-3102, A Second Generation NS5A Inhibitor, Demonstrates Potent Antiviral Activity (single-dose) in Patients with Genotype 1A HCV Infection Despite the Presence of Baseline NS5A-Resistant Variants ........http://www.natap.org/2013/EASL/EASL_85.htm
EASL/2013: FINDINGS FROM CLINICAL VIROLOGY STUDIES ON ACH-3102 ARE CONSISTENT WITH PRECLINICAL OBSERVATIONS ON ITS IMPROVED POTENCY AGAINST GENOTYPE-1A HCV AND RESISTANT VARIANTS......http://www.natap.org/2013/EASL/EASL_84.htm
|
| |
|
|
|
|
|
